ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research American College of Cardiology

The VICTORION-INIATATE study demonstrated that initiating inclisiran, a highly potent lipid-lowering therapy, upon failure to achieve lipid targets with statins, yielded superior outcomes compared to standard care. This approach facilitated a greater proportion of patients in reaching LDL-C targets recommended by current guidelines. Presently, the conventional management of cholesterol disorders in the US routinely falls short of attaining treatment goals for the majority of patients. 

In this interview, Michael J. Koren, MD, FACC, and C. Noel Bairey Merz, MD, FACC discuss results from the VICTORION-INITIATE randomized trial. 

Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment. 

 In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

It's becoming increasingly evident that alongside top-notch clinical expertise, the CV specialist of the future must be surrounded by a multi-talented, diverse team to provide optimal patient care. In addition, it is crucial that the clinician and CV organization engage in non-clinical competencies to enhance value for patients, the healthcare system, and society. MedAxiom and ACC collaborate synergistically toward achieving these goals. 

In this interview, Jerry Blackwell MD, MBA, FACC and Joseph E. Marine MD, MBA, FACC, discuss The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape. 

  

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk. 

 In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial. 

About half of patients with chronic heart failure have an ejection fraction >40%. Therapy for patients in this group has been challenging until recently; few therapies have been effective in improving clinical outcomes in this population. Recently, data from several clinical trials of SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), Angiotensin-receptor neprilysin inhibitors (ARNI), and GLP-1 receptor agonists, however, have offered potential for targeted therapy in this population. Meanwhile, device therapy continues to evolve for this group.  

 In this interview, Clyde W. Yancy, MD, MSc, MACC, and Akshay S. Desai, MD, MPH, discuss How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians. 

 Subscribe on Apple Podcasts | Subscribe to ACCEL 

Aortic valve disease is often identified too late before clinicans can provide meaningful prevention. 

Identifying aortic valve calcium opens the door for potential prevention of progression: a phenotype researchers could build randomized controlled trials around. 

  

In this interview, Richard A. Chazal MD, MACC and Michael J. Blaha, MD, MPH discuss Prevalence of Aortic Valve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis. 

  

Subscribe on Apple Podcasts | Subscribe to ACCEL